

February 27, 2025

Dear Colleagues,

The Oregon State Public Health Laboratory (OSPHL) is pleased to inform you that our laboratory will resume pyrazinamide (PZA) testing on the BD BACTEC MGIT™ 960 platform beginning with isolates received or cultured beginning March 3, 2025. Please share this notice with your colleagues who may need this information.

**Will OSPHL be able to continue testing for PZA susceptibility?**

OSPHL currently has sufficient supplies for approximately four months' of PZA susceptibility testing. We anticipate testing will continue, as BD has informed its clients that additional supply will be available in early 2025. If this changes, we will notify clients of our testing plans.

**What caused the PZA testing pause at OSPHL?**

In August 2024, OSPHL notified clients and colleagues (pdf) that Becton, Dickinson and Company (BD) recently released a recall notice affecting the MGIT™ pyrazinamide (PZA) Kit used by OSPHL for drug susceptibility testing. As a result of the recall, OSPHL was unable to obtain kits for testing until recently. ([August 1, 2024 letter \(pdf\)](#))

Thank you for your collaboration and understanding during this testing pause. Please contact our laboratory team with questions at 503-693-4100 or:

- Matthew Burns, General Microbiology Section Manager,  
[matthew.c.burns@oha.oregon.gov](mailto:matthew.c.burns@oha.oregon.gov)
- Lillian McLitus, Interim Tuberculosis Testing Lead,  
[lillian.mclitus@oha.oregon.gov](mailto:lillian.mclitus@oha.oregon.gov)

Sincerely,

Patrick Luedtke, MD, MPH  
Medical Director, OSPHL

Matthew Burns, MSc  
General Microbiology Manager, OSPHL